Cogent Biosciences, Inc. COGT
- bezuclastinib — Non-Advanced Systemic Mastocytosis Phase 2
- bezuclastinib — Gastrointestinal Stromal Tumor NDA Submitted
- bezuclastinib — Gastrointestinal Stromal Tumors NDA Submitted
KIT D816V (1 companies · 3 programs)
Companies with an active program directed at KIT D816V.